This provides an indication of new drugs being brought to market, the end point of drug development at which those interventions are deemed effective and can be made available to the public. This provides one measure of the innovative output of the research system. However, not all health and biomedical research projects are aimed at producing this type of product, so this only provides a partial picture. Source: European Medicines Agency
| Year | Number of New Active Substances approaved by EMA |
|---|---|
| 2012 | 32.0 |
| 2013 | 38.0 |
| 2014 | 41.0 |
| 2015 | 39.0 |
| 2016 | 27.0 |
| 2017 | 35.0 |
| 2018 | 42.0 |
| 2019 | 30.0 |
| 2020 | 39.0 |